Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. - Wikidata - wikimedia - TriplyDB

Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review.

Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review.

http://www.wikidata.org/entity/Q34969496

about

HIV Drug Resistance: Problems and Perspectives Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors.Understanding HIV latency: the road to an HIV cure HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda The root extract of the medicinal plant Pelargonium sidoides is a potent HIV-1 attachment inhibitor HIV-1 diversity, transmission dynamics and primary drug resistance in Angola Virological failure and HIV-1 drug resistance mutations among naive and antiretroviral pre-treated patients entering the ESTHER program of Calmette Hospital in Cambodia Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial HIV-1 Variants and Drug Resistance in Pregnant Women from Bata (Equatorial Guinea): 2012-2013 Detectable Viral Load in Late Pregnancy among Women in the Rwanda Option B+ PMTCT Program: Enrollment Results from the Kabeho Study Simultaneous detection of major drug resistance mutations in the protease and reverse transcriptase genes for HIV-1 subtype C by use of a multiplex allele-specific assay Virological success after 12 and 24 months of antiretroviral therapy in sub-Saharan Africa: Comparing results of trials, cohorts and cross-sectional studies using a systematic review and meta-analysis.Misdiagnosis of HIV treatment failure based on clinical and immunological criteria in Eastern and Central Kenya Validation of an oligonucleotide ligation assay for quantification of human immunodeficiency virus type 1 drug-resistant mutants by use of massively parallel sequencing Field study of dried blood spot specimens for HIV-1 drug resistance genotyping Oligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya.When to start antiretroviral therapy: the need for an evidence base during early HIV infection Phylogenetic studies of transmission dynamics in generalized HIV epidemics: an essential tool where the burden is greatest?Persistent difficulties in switching to second-line ART in sub-saharan Africa--a systematic review and meta-analysis.Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus Study, Dar es Salaam, Tanzania Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20 Assessing transmissibility of HIV-1 drug resistance mutations from treated and from drug-naive individuals.Targeting HIV Prevention Based on Molecular Epidemiology Among Deeply Sampled Subnetworks of Men Who Have Sex With Men Low Virologic Failure and Drug Resistance among HIV-Infected Patients Receiving Hospital-Based ART While Care and Outreach through Community in Guangxi, China.From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.Prevalence of Transmitted HIV Drug Resistance Among Recently Infected Persons in San Diego, CA 1996-2013.Emerging antiretroviral drug resistance in sub-Saharan Africa: novel affordable technologies are needed to provide resistance testing for individual and public health benefits.Sharp increase in rates of HIV transmitted drug resistance at antenatal clinics in Botswana demonstrates the need for routine surveillance Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine HIV virological failure and drug resistance in a cohort of Tanzanian HIV-infected adults.Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Côte d'Ivoire, West Africa.HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study Journey towards universal viral load monitoring in Maputo, Mozambique: many gaps, but encouraging signs.Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children.Patterns of HIV-1 Drug-Resistance Mutations among Patients Failing First-Line Antiretroviral Treatment in South India.Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda.Drug resistance mutation profiles of the drug-naïve and first-line regimen-treated HIV-1-infected population of Suzhou, China.

P2860

Q26864534-3940F01A-2075-4EF1-9671-C1874B571DEA Q27324263-F45270E2-B6FD-41C1-88A6-EA0883426C4A Q28085296-CAF11FFA-8869-4AD2-A521-1F252DEB77F1 Q28271593-573E3944-9DC7-40F0-B393-68B3F5101E56 Q28535266-4D309AAF-B9ED-4036-86E5-CD3AD60098BB Q28539308-32B31CB8-BE7E-45B6-9197-3FC4DAA05F46 Q28542528-9C66B77E-9372-4156-9432-18729CFEAFCF Q28542625-84E9C700-9951-42CB-8D21-513A8DE994DB Q28545866-81896C72-951C-4E3F-B9C7-23090BA05671 Q28552171-2FEC633D-FFBB-4976-8F19-642018D09115 Q28553083-3170D8DD-5FF0-4890-B931-B4738E09457F Q28555187-44BEFF28-D0D6-4A63-AE16-4AEF16E7DD0D Q28660673-0D28B729-E20C-41C0-A73B-4C466AA1DD14 Q33584656-DD48DCBD-734E-43C4-BF74-E6C10B6C9903 Q33759577-04147F0F-C536-4A0D-A26C-82A173213AD5 Q33899918-A07A318A-2BB0-4D32-887E-2988F841A0A2 Q34058841-70FC7BA9-6FE4-4B05-99BA-03A5ECEA72E0 Q34339340-620D74AB-8593-4E77-AD23-7D55C2AE8894 Q34773308-7F649940-80D7-43E4-ABF5-B9C4103CC5D2 Q35006672-8B25FD44-3705-4F5F-9EFD-345031E3E85B Q35077695-7BB7FC20-FE32-4B83-87D8-B56C3543A191 Q35357751-3C675F6F-7F71-4CB0-A312-0B7808BD473D Q35909838-F2091941-1BEC-45CB-8CF3-75867C846D06 Q36061979-4474CAA2-7216-464D-8537-75D9CDA697A9 Q36141239-AB172EC5-BE46-4041-BD82-AE1BBEF4B20A Q36209093-3B55FE19-9670-4B12-A54F-EE77E767D057 Q36232454-44F15100-B8C5-4088-90D4-B8E6CD323E63 Q36434250-1B1AA79B-56DE-4008-83B2-6881AB44C937 Q36460056-0AB810C8-3850-4E3C-9E4E-BFDF85FF317B Q36669337-1B7E4ED0-2F5D-4370-BC94-FFECDF6A4C18 Q36794795-61D2420D-298A-4A73-AD89-AD6BA93227B4 Q36852626-75FDEB00-8B50-43DD-8FF6-466C4AE64CCD Q36977381-F1A65462-8E37-4175-8151-ED543D97D46A Q37326870-62D28A43-61DD-4BD0-82FD-5B6A99D2E44B Q37580882-652FD24F-39AB-4ECA-A781-D343F9E5763B Q38556931-9714EE88-CD13-4AE3-A6C0-63DC4057D533 Q38849814-4E3025BC-9E94-462E-A5B1-FF4A2813EC1B Q38962278-05CDFBD7-E50C-4257-9E79-D91AD1D21A41 Q39297017-9D5ED19F-5260-44B1-9921-D3884DA194B1 Q40088267-0538DF51-830E-4D8E-952F-80ED3E6BD785

P2860

Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review.

http://www.wikidata.org/entity/Q34969496

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Rates of emergence of HIV drug ...... settings: a systematic review.

@ast

Rates of emergence of HIV drug ...... settings: a systematic review.

@en

Rates of emergence of HIV drug ...... settings: a systematic review.

@nl

type

label

Rates of emergence of HIV drug ...... settings: a systematic review.

@ast

Rates of emergence of HIV drug ...... settings: a systematic review.

@en

Rates of emergence of HIV drug ...... settings: a systematic review.

@nl

prefLabel

Rates of emergence of HIV drug ...... settings: a systematic review.

@ast

Rates of emergence of HIV drug ...... settings: a systematic review.

@en

Rates of emergence of HIV drug ...... settings: a systematic review.

@nl

P1433

Q34969496-AB8C3A0D-022E-474F-866D-BECEC2851893

P1476

Q34969496-4F645E30-FE32-4C53-BA43-F13ED299ED39

P2093

Q34969496-E6E6F6C3-3807-4D8C-8905-4E38CA057955

P2860

Q34969496-111ADB9B-7127-46A1-BBF2-E7FF79E9BC7E

Q34969496-12929675-2E3C-4B27-9320-89C264425EE6

Q34969496-20BDA4FD-1E95-4B30-9524-DF755EDDA20E

Q34969496-20F31B95-BAE8-4479-918B-449476A53CCC

Q34969496-21DB24D3-E100-4A16-8F87-DD1AD9EC6C0B

Q34969496-235E3062-D3A1-4AE0-8D8D-8DDD82C92B14

Q34969496-2C0F294E-31A3-4F25-BBEC-8D768180E29E

Q34969496-328E0457-86F2-40C2-8A9C-85773755BCB1

Q34969496-34A62079-A7C4-4BB9-9018-C8B4F6E6F1B6

Q34969496-3673DD91-4BB7-4C96-8670-A4A98E3A3C93

P304

Q34969496-1FDE7FA1-298B-4790-91B2-F7C19666EEF4

P31

Q34969496-FD653A2A-E6D9-4568-B49C-B782875A31F5

P356

Q34969496-070CA0DB-ACDB-48BD-B092-F69D6D988C37

P433

Q34969496-00377521-CF67-48A6-9F62-4EC26FAF6A2A

P478

Q34969496-7D345DFC-445E-426D-80C8-521CA3B3B762

P50

Q34969496-E39E4724-E519-4EA0-9B32-9452693E88AE

P577

Q34969496-DADA28E7-CA22-43BF-8E35-D8FB630E65C9

P698

Q34969496-9D0F933E-AB8A-40E4-AB68-2286E00454A4

P932

Q34969496-FD13A3DE-05B7-436E-9BA3-D1241ACA2223

P356

P1433

Antiviral Therapy

P1476

Rates of emergence of HIV drug ...... settings: a systematic review.

@en

P2093

Douglas D Richman

http://www.w3.org/2001/XMLSchema#string

P2860

The President's Emergency Plan for AIDS Relief in Africa: an evaluation of outcomes

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update

Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa

Sentinel surveillance of HIV-1 transmitted drug resistance, acute infection and recent infection

High HIV type 1 group M pol diversity and low rate of antiretroviral resistance mutations among the uniformed services in Kinshasa, Democratic Republic of the Congo.

Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings.

Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature.

Outcomes after virologic failure of first-line ART in South Africa

Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.

P304

115-123

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3851/IMP2437

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Kathryn M Stadeli

P577

2012-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23052978

http://www.w3.org/2001/XMLSchema#string

P932

4295493

http://www.w3.org/2001/XMLSchema#string